News Updates
More Articles
- BioNTech, OncoC4 sign licensing deal for CTLA-4 antibody
- BioNTech to open research, manufacturing site in Israel
- Sanofi, Regeneron tout positive data on dupilumab for COPD
- Takeda building $733M plasma therapy production facility
- Bahrain Pharma begins production
BioNTech, OncoC4 sign licensing deal for CTLA-4 antibody
BioNTech said it has signed an exclusive global licensing and collaboration deal with OncoC4 for the development and commercialization of its anti-CTLA-4 antibody candidate ONC-392 for solid tumors. As part of the agreement, a $200 million upfront payment will be made to OncoC4, which will also be eligible for milestone payments related to commercial, development and regulatory achievements as well as double-digit tiered royalty payments. BioSpace (San Francisco) (3/21)
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!